For the quarter ending 2025-09-30, LENZ had -$12,323K decrease in cash & cash equivalents over the period. -$9,027K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -16,700 | -29,531 |
| Depreciation and amortization | 125 | 55 |
| Loss on impairment of operating right-of-use assets and related property and equipment | 0 | 82 |
| Accretion of discounts on marketable securities | 779 | 2,022 |
| Change in fair value of preferred stock warrants | 0 | 0 |
| Share-based compensation expense | 3,469 | 5,400 |
| Inventory | 949 | - |
| Prepaid expenses and other current assets | -93 | 1,196 |
| Accounts payable | 1,694 | -1,628 |
| Accrued liabilities | 4,459 | 1,487 |
| Other assets | 0 | 204 |
| Net cash used in operating activities | -8,588 | -27,557 |
| Purchases of marketable securities | 56,306 | 91,385 |
| Proceeds from maturities of marketable securities | 52,412 | 110,210 |
| Purchases of property and equipment | 439 | 350 |
| Net cash provided by (used in) investing activities | -4,333 | 18,475 |
| Proceeds from issuance of common stock, net of issuance costs-At The Market Offerings | 0 | 26,067 |
| Proceeds from exercises of stock options | 598 | 240 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 225 |
| Cash, cash equivalents, and restricted cash acquired in connection with the merger | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs-Private Placement | 0 | 0 |
| Merger transaction costs | 0 | 0 |
| Net cash provided by financing activities | 598 | 26,532 |
| Net increase in cash, cash equivalents, and restricted cash | -12,323 | 17,450 |
| Cash and cash equivalents at beginning of period | 20,272 | - |
| Cash and cash equivalents at end of period | 25,399 | - |
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)